Scientist experimenting in a pharma lab

Orphan drugs encounter challenges that extend from their initial discovery to eventual launch, primarily due to the restricted patient numbers and niche markets associated with therapies for rare diseases. In an August 2023 study involving close to 400 professionals within the orphan drugs sector, Renejix investigated the pivotal factors and obstacles spanning both the development and commercialization stages. Despite grappling with limitations in skills and resources, the visionary entities that confront these hurdles are frequently driven by a determination to aid patients who currently lack alternative solutions.


author avatar
Sridhar Gumudavelli
Sridhar Gumudavelli serves as the Vice President of Formulation R&D at Renejix Pharma Solutions, where he brings a wealth of knowledge and experience to the table. His leadership is instrumental in navigating the complex process of drug formulation, leveraging a variety of technologies to enhance drug absorption, bioavailability, and patient compliance.Sridhar’s expertise is not just limited to his hands-on experience; he is also an innovator with several patents filed under his name. These patents reflect his contributions to advancing drug delivery systems, showcasing his ability to tackle some of the most challenging problems in pharmaceutical sciences for the past 30+ years.

Similar Posts